ASEP Medical Holdings (ASEP Medical Holdings) Common Stock : $17.92 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings Common Stock?

ASEP Medical Holdings's quarterly common stock increased from Jun. 2023 ($16.14 Mil) to Sep. 2023 ($16.72 Mil) and increased from Sep. 2023 ($16.72 Mil) to Dec. 2023 ($17.92 Mil).

ASEP Medical Holdings's annual common stock declined from Dec. 2021 ($15.21 Mil) to Dec. 2022 ($14.61 Mil) but then increased from Dec. 2022 ($14.61 Mil) to Dec. 2023 ($17.92 Mil).

ASEP Medical Holdings Common Stock Historical Data

The historical data trend for ASEP Medical Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings Common Stock Chart

ASEP Medical Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Common Stock

15.21

14.61

17.92

ASEP Medical Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial							14.61	14.92	16.14	16.72	17.92

ASEP Medical Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

JJ8:Germany ASEP:Canada

Address

730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7

Website

https://www.asepmedical.com

ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.